Table 1.
Clinical and laboratory data of the 44 patients with and without HCC
| Gender | Age in year | HBeAg: anti‐HBe | HBV‐DNA (LGE/mL) | Follow‐up time (months) | WBC( × 103/µL) | RBC( × 106/µL) | PLT( × 103/µL) | AST(IU/L) | ALT(IU/L) | ALB(g/dL) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non‐HCC group (B) | M:F = 14:6 | 41.35 ± 9.55 | 18:2 | 6.91 ± 2.90 | – | 5.09 ± 1.01 | 4.53 ± 0.45 | 182.55 ± 70.57 | 159.50 ± 415.58 | 214.55 ± 410.16 | 4.16 ± 0.34 |
| Non‐HCC group (A) | – | 48.55 ± 8.56 | 18:2 | 6.31 ± 1.74 | 87.45 ± 36.43 | 5.27 ± 1.47 | 4.36 ± 0.48 | 183.15 ± 70.95 | 147.40 ± 173.11 | 209.55 ± 240.01 | 4.02 ± 0.70 |
| HCC group (B) | M:F = 21:3 | 41.29 ± 10.51 | 14:10 | 6.21 ± 1.73 | – | 5.42 ± 1.62 | 4.54 ± 0.55 | 133.25 ± 63.93 | 89.96 ± 101.33 | 98.04 ± 92.79 | 4.17 ± 0.48 |
| HCC group (A) | – | 47.33 ± 9.14 | 15:9 | 5.48 ± 1.21 | 77.20 ± 41.86 | 4.68 ± 1.19 | 4.42 ± 0.55 | 118.33 ± 59.60 | 51.17 ± 36.86 | 49.50 ± 35.23 | 4.02 ± 0.57 |
| P (non‐HCC B vs HCC B) | 0.26 | 0.99 | 0.04 | 0.13 | – | 0.43 | 0.94 | 0.02 | 0.43 | 0.18 | 0.90 |
| P (non‐HCC A vs HCC A) | – | 0.65 | 0.04 | 0.39 | 0.40 | 0.15 | 0.74 | < 0.01 | 0.01 | < 0.01 | 1.00 |
The significance of differences (P‐value) in the indicated groups is shown. P < 0.05 is indicated by italic type. Non‐HCC group (B): at the beginning of follow‐up in patients who did not develop HCC. Non‐HCC group (A): at the end of follow‐up in patients who did not develop HCC. HCC group (B): at the beginning of follow‐up in patients who developed HCC. HCC group (A): at the diagnosis of HCC in patients who developed HCC. ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBeAg, hepatitis B e antigen; HCC, hepatocellular carcinoma; LGE/mL, logarithm of genomic equivalent per milliliter; PLT, platelet; RBC, red blood cells; WBC, white blood cells.